Brentuximab vedotin

Synonyms: SGN-035; Adcetris

Catalog No.D4045 Purity:98.93%

Brentuximab vedotin (SGN-35; Adcetris,cAC10-vcMMAE) is an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE). Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma.

CAS No. 914088-09-8

Click to purchase products related to Brentuximab vedotin

Purity & Quality Control

Batch: D404501 Purity: 98.93% Protein concentration: 9.36mg/ml Endotoxin Level: ＜1EU/mg

98.93

Choose Selective CD markers Inhibitors

Name	Citation	CD38	CD45	CD39	CD88	CD73	Others
RBN013209	0	++
MK-0159	0	+++
CD38 inhibitor 1 (compound 78c)	5	+++
AB680	0					++++
NQ301	1		+				TXA2 receptor
SodiuM Metatungstate	3			++
PMX-53				✔
LY-3475070					✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Brentuximab vedotin (SGN-35; Adcetris,cAC10-vcMMAE) is an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE). Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma.

References
[1] van de Donk NW, et al. MAbs. 2012;4(4):458-465.

References

[1] van de Donk NW, et al. MAbs. 2012;4(4):458-465.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	914088-09-8
DAR	4.2
ADC antiody	Brentuximab
ADC cytotoxin	MMAE
Formulation	1xPBS
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.